Results 141 to 150 of about 94,073 (238)

Myeloproliferative neoplasm harboring both monosomy 7 and an ALK/ROS1 fusion gene: Proposal for a new disease entity

open access: yes
Introduction We present a case of a 9‐year‐old girl diagnosed with a myeloproliferative neoplasm (MPN) harboring both monosomy 7 and an ALK/ROS1 fusion gene.
Toshihiko Imamura   +6 more
core   +1 more source

No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients

open access: yes, 2019
Wille K, Sadjadian P, Becker T, Kolatzki V, Fuchs C, Griesshammer M. No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients.
Becker, T.   +5 more
core  

Low-dose methotrexate in myeloproliferative neoplasm models

open access: yesHaematologica, 2017
Kavitha Chinnaiya   +10 more
doaj   +1 more source

Targeted Next-Generation Sequencing of JAK2, CALR, and MPL in 10 326 Patients With Suspected Myeloproliferative Neoplasm. [PDF]

open access: yesAm J Hematol
Rigolot L   +19 more
europepmc   +1 more source

Sotatercept for the Treatment of Myeloproliferative Neoplasm-Associated Group 5 Pulmonary Hypertension. [PDF]

open access: yesJACC CardioOncol
Ali HR   +9 more
europepmc   +1 more source

Stage-Specific Degradation of Cyclin D3 Orchestrates Myelopoiesis and Restrains Myeloproliferative Neoplasm Development. [PDF]

open access: yesCancer Res
Mucha B   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy